

Review Article

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer

Pascale Quatresooz,¹ Trinh Hermanns-Lê,¹ Gérald E. Piérard,^{1,2} Philippe Humbert,^{2,3,4} Philippe Delvenne,¹ and Claudine Piérard-Franchimont¹

¹Department of Dermatopathology, University Hospital of Liège, 4000 Liège, Belgium

²Faculty of Medicine, University of Franche-Comté, 25000 Besançon, France

³Department of Dermatology, University Hospital of Besançon, 25000 Besançon, France

⁴Inserm Research Unit U645, IFR133, 25000 Besançon, France

Correspondence should be addressed to Gérald E. Piérard, gerald.pierard@ulg.ac.be

Received 31 January 2012; Revised 5 March 2012; Accepted 5 March 2012

Academic Editor: Enzo Berardesca

Copyright © 2012 Pascale Quatresooz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.

1. Introduction

Disturbed immune-mediated inflammatory reactions are involved in the pathogenesis of psoriasis and its comorbidities [1]. There is evidence that the combined epidermal and microvasculature hyperplasia results from a response to the immune cell infiltrate present in the skin [2–4]. In recent years, some specific inflammatory cytokine pathways have represented promising or established therapeutic targets [1–6]. In particular, biologicals directed to tumor necrosis factor (TNF)- α , interleukin (IL)-12, IL-23, as well as CD4⁺ T helper (Th) 1 and Th17 effector cells fitted with the psoriasis pathobiology [7, 8].

2. The IL-12 / IL-23 Connection

IL-12 and IL-23 are structurally related cytokines that upregulate T-cell immune responses [9]. IL-12 is a heterodimeric protein consisting of the two disulfide-linked, glycosylated p35 and p40 subunits. This cytokine is secreted by dendritic

antigen-presenting cells in response to inflammatory stimuli or infections. The IL-12 cytokine activates natural killer (NK) and T-cell responses, including naive CD4⁺ T-cell differentiation toward the CD4⁺ Th1 phenotype [9–11]. The heterodimeric IL23 cytokine contains the identical p40 subunit disulfide-linked to a p19 subunit [11]. Following activation by IL-6 and transforming growth factor (TGF)- β , IL-23 in concert with TNF α supports the development of Th17 cells [9–13].

The p40 subunit of both IL-12 and IL-23 binds to the IL-12 receptor- β 1 (IL-12R β 1) [14, 15]. The IL-12p35 and the IL-23p19 subunits bind to IL-12R β 2 and IL-23R, respectively. These distinct binding processes account for the cytokine biological specificities [11, 14, 15]. Thus, despite some structural similarities between IL-12 and IL-23, they control distinct immunological pathways. IL-12 promotes the development of Th1 populations producing interferon (IFN)- γ , TNF- α , and IL-2. By contrast, IL-23 in combination with IL-21 and TGF β drives the development of CD4⁺ Th17 populations producing IL-17, IL-22, TNF- α , and IL-1 β [16].

3. Psoriasis Immunopathogenesis

Psoriasis apparently results from the activation of an abnormal immune response leading to excessive keratinocyte proliferation and global epidermal thickening. In particular, cytokines produced by Th1 and Th17 cell populations play a pivotal role in the development and maintenance of psoriatic lesions [13–15, 17–19]. The p40-containing cytokines are involved in the psoriasis pathogenesis [17] because there is overexpression of the IL-12p40 and the IL-23p40 in psoriasis plaques [20–22]. Gene polymorphisms encoding the shared p40 subunit or one of the components of the IL-23 receptor (IL-23R) complex are linked to psoriasis [23]. An uncommon IL-23R coding variant protecting against Crohn's disease appears to confer protection against psoriasis [24, 25]. Gene expression levels of IL-12p40, IFN- γ , and IL-23p49 are raised in psoriatic lesions [21, 23, 26]. Both IL-17 and IL-22 promote epidermal proliferation and remodelling, through activation of the keratinocyte transcription factor Stat3, and upregulate keratinocyte host defence proteins, including human β -defensin (H β D)-2 [19, 27]. IFN- γ in concert with Stat 1 activates keratinocytes to upregulate major histocompatibility complex class II, while both intracellular adhesion molecules (ICAM) and TNF α contribute to the development of psoriatic plaques [1, 18, 28, 29]. In addition, IL-23 drives monocytes to differentiate into dendritic cells [30]. This might account for the presence of many factor XIIIa+ dermal dendrocytes.

Th1 and Th17 cells are involved in the psoriasis pathobiology following secretion of a series of inflammatory cytokines, including IFN- γ , IL-17, and IL-22, that in turn activate keratinocytes to proliferate and secrete additional proinflammatory mediators [5]. The IL-12 and IL-23 cytokines produce a downstream impact on Th1 and Th17 cell activation, as well as keratinocyte triggering. Accordingly, any therapeutic agent designed to block IL-12 and IL-23 likely abates the upregulation of IFN- γ , IL-17, and IL-22 by both Th1 and Th17 cells [5].

Th17 cells play a central role in the development of psoriasis [2, 31]. IL-23 represents the major regulator of Th17 cells. These cells conduct immunosurveillance in the epidermis and secrete IL-17A, IL-17F, and IL-22 [32]. In psoriatic lesions, the proinflammatory IL-17 leads to the production of other cytokines and angiogenic factors, committing naive T cells to the Th17 lineage and creating a positive feedback loop for Th17 inflammation. IL-22 acts on keratinocytes through the IL-22 and IL-10 receptors, resulting in hyperproliferation and altered keratinocyte maturation leading to the typical acanthosis of psoriatic lesions [33, 34]. IL-17 and IL-22 produce a synergist stimulation of keratinocytes to be resistant to microbial infection through the expression of antimicrobial peptides. Some Th17 cells produce IL-17 only, while Th22 cells solely produce IL-22 [35, 36].

Both IL-12 and IL-23 are overexpressed in lesional psoriatic skin. However, the p40 subunit was used as a surrogate for assessing IL-12 expression. Thus, no differentiation was possible between the presence of IL-12 and IL-23 [37–40]. A pivotal study showed RNA upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23p19 subunit, but

not an increased expression of the IL-12p35 subunit [38]. Such finding suggested that IL-23 was more involved in the maintenance of psoriatic lesions than IL-12. Additionally, IL-23 is a more potent activator of keratinocyte proliferation than IL-12 [39, 40].

4. Ustekinumab

The psoriasis immunopathogenesis has provided new therapeutic options in recent years [7]. Among recent breakthroughs, ustekinumab (Stelara, Janssen Pharmaceutica, Beerse, Belgium) is a fully human monoclonal antibody of the IgG1 class. It is directed to the shared p40 subunit of both IL-12 and IL-23 [41–43]. Thus, the drug neutralizes the bioactivities of both cytokines by blocking interaction with the IL-12R β 1 cell surface receptor. The pharmacological characteristics and both the clinical efficacy and tolerability of ustekinumab are clearly proven in patients with chronic moderate to severe plaque psoriasis, including subjects with psoriatic onychopathy and psoriatic arthritis [8, 43–46].

IL-23 expression is significantly increased in the psoriatic epidermis [5, 38]. IL-23 messenger RNA expression is significantly higher in lesional skin of psoriatic patients as compared with healthy skin in the same patients [5, 38]. IL-23 secretion by monocytes and mature dendritic cells derived from patients with psoriasis is unusually high [38]. This cytokine promotes survival and proliferation of Th17 cells [47–51]. As a result, Th17 cytokines, such as IL-17, stimulate keratinocyte proliferation enabling further stimulation of keratinocyte proliferation in psoriatic lesions [6, 29].

The therapeutic efficacy of ustekinumab is obtained after IL-12 and IL-23 inhibition leading to the abated expression of cell surface markers associated with skin homing (CLA), activation of anti-inflammatory cytokines including IL-5, and inhibition of the secretion of the proinflammatory cytokines IFN γ , IL-2, IL-8, IL-10, IL-17A, and TNF α . A reduction in CD4+ Th cells and NK cells was reported after a single dose of ustekinumab. However, changes varied across time and did not appear to be dose dependent. Ustekinumab pharmacokinetics is notably affected by body weight. This aspect is particularly important to consider in case of metabolic syndrome comorbidity.

5. Beyond Psoriasis

Recent clinical trials conducted in humans emphasized the crucial role of Th17 cells boosted by IL-23 in the immunopathogenesis of several other inflammatory skin diseases, including allergic contact dermatitis, systemic scleroderma, and sarcoidosis [52–58]. In addition, the IL-23/Th17 axis appears to play a prominent role in the development of other diseases with possible cutaneous involvement. These include systemic lupus erythematosus [59, 60], rheumatoid arthritis [61], inflammatory bowel disease [62], and Behçet disease [63]. Considering the major role of IL-23-dependent Th17 cells in several skin diseases, future indications for IL-23 pathway inhibitors will probably emerge in a field much more broader than currently documented.

At present, the advent of biological therapies has already revolutionized the treatment of autoimmune diseases beyond psoriasis, including autoimmune arthritides, and inflammatory bowel diseases.

6. Conclusion

Psoriasis is a frequent chronic relapsing immunoinflammatory dermatitis particularly triggered by the Th17/IL-23 axis. The long-term limitations of conventional systemic psoriasis therapies because of the potential for severe renal, hepatic, and pulmonary adverse events have led to the development of biotherapies. An increased understanding of the immunopathogenesis of psoriasis helped focusing on specific targets. These agents alter specific immunologic pathways involved in the development of the disease, including some cytokine productions. At present, it appears that IL-23 is more involved than IL-12 in the pathogenesis of psoriasis.

Ustekinumab is a monoclonal antibody to the common p40 subunit shared by IL-12 and IL-23. It represents a masterpiece in the treatment of plaque psoriasis. Other conditions including psoriatic arthritis, Crohn's disease, and some other autoimmune diseases are expected to become recognized indications for the drug.

References

- [1] G. E. Piérard, C. Piérard-Franchimont, G. Szepeituk, P. Paquet, and P. Quatresooz, "The therapeutic potential of TNF- α antagonists for skin psoriasis comorbidities," *Expert Opinion on Biological Therapy*, vol. 10, no. 8, pp. 1197–1208, 2010.
- [2] B. J. Nickoloff and F. O. Nestle, "Recent insights into the immuno-pathogenesis of psoriasis provide new therapeutic opportunities," *Journal of Clinical Investigation*, vol. 113, no. 12, pp. 1664–1675, 2004.
- [3] C. E. Griffiths and J. N. Barker, "Pathogenesis and clinical features of psoriasis," *The Lancet*, vol. 370, no. 9583, pp. 263–271, 2007.
- [4] F. O. Nestle, D. H. Kaplan, and J. Barker, "Mechanisms of disease: psoriasis," *New England Journal of Medicine*, vol. 361, no. 5, pp. 444–509, 2009.
- [5] M. Kurzeja, L. Rudnicka, and M. Olszewska, "New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab," *American Journal of Clinical Dermatology*, vol. 12, no. 2, pp. 113–125, 2011.
- [6] N. Yeilding, P. Szapary, C. Brodmerkel et al., "Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives," *Annals of the New York Academy of Sciences*, vol. 1222, no. 1, pp. 30–39, 2011.
- [7] B. J. Nickoloff and F. O. Nestle, "Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities," *Journal of Clinical Investigation*, vol. 113, no. 12, pp. 1664–1675, 2004.
- [8] A. Menter, A. Gottlieb, S. R. Feldman et al., "Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics," *Journal of the American Academy of Dermatology*, vol. 58, no. 5, pp. 826–850, 2008.
- [9] L. Lyakh, G. Trinchieri, L. Provezza, G. Carra, and F. Gerosa, "Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans," *Immunological Reviews*, vol. 226, no. 1, pp. 112–131, 2008.
- [10] G. Trinchieri, "Interleukin-12 and the regulation of innate resistance and adaptive immunity," *Nature Reviews Immunology*, vol. 3, no. 2, pp. 133–146, 2003.
- [11] B. Oppmann, R. Lesley, B. Blom et al., "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12," *Immunity*, vol. 13, no. 5, pp. 715–725, 2000.
- [12] S. Aggarwal, N. Ghilardi, M. H. Xie, F. J. De Sauvage, and A. L. Gurney, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17," *Journal of Biological Chemistry*, vol. 278, no. 3, pp. 1910–1914, 2003.
- [13] N. J. Wilson, K. Boniface, J. R. Chan et al., "Development, cytokine profile and function of human interleukin 17-producing helper T cells," *Nature Immunology*, vol. 8, no. 9, pp. 950–957, 2007.
- [14] D. H. Presky, H. Yang, L. J. Minetti et al., "A functional interleukin 12 receptor complex is composed of two β -type cytokine receptor subunits," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 24, pp. 14002–14007, 1996.
- [15] C. Parham, M. Chirica, J. Timans et al., "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R β 1 and a novel cytokine receptor subunit, IL-23R," *Journal of Immunology*, vol. 168, no. 11, pp. 5699–5708, 2002.
- [16] L. Yang, D. E. Anderson, C. Baecher-Allan et al., "IL-21 and TGF- β are required for differentiation of human T H17 cells," *Nature*, vol. 454, no. 7202, pp. 350–352, 2008.
- [17] F. O. Nestle and C. Conrad, "The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis," *Journal of Investigative Dermatology*, vol. 123, no. 6, pp. 14–15, 2004.
- [18] B. J. Nickoloff, "Cracking the cytokine code in psoriasis," *Nature Medicine*, vol. 13, no. 3, pp. 242–244, 2007.
- [19] M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al., "Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells," *Journal of Investigative Dermatology*, vol. 128, no. 5, pp. 1207–1211, 2008.
- [20] G. Piskin, R. M. R. Sylva-Steenland, J. D. Bos, and M. B. M. Teunissen, "In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin," *Journal of Immunology*, vol. 176, no. 3, pp. 1908–1915, 2006.
- [21] D. C. Torti and S. R. Feldman, "Interleukin-12, interleukin-23, and psoriasis: current prospects," *Journal of the American Academy of Dermatology*, vol. 57, no. 6, pp. 1059–1068, 2007.
- [22] A. B. Kimball, K. B. Gordon, R. G. Langley, A. Menter, E. K. Chartash, and J. Valdes, "Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial," *Archives of Dermatology*, vol. 144, no. 2, pp. 200–207, 2008.
- [23] M. Cargill, S. J. Schrodi, M. Chang et al., "A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes," *American Journal of Human Genetics*, vol. 80, no. 2, pp. 273–290, 2007.
- [24] R. H. Duerr, K. D. Taylor, S. R. Brant et al., "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene," *Science*, vol. 314, no. 5804, pp. 1461–1463, 2006.

- [25] F. Capon, P. Di Meglio, J. Szaub et al., "Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis," *Human Genetics*, vol. 122, no. 2, pp. 201–206, 2007.
- [26] L. C. Zaba, M. Suárez-Fariñas, J. Fuentes-Duculan et al., "Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes," *Journal of Allergy and Clinical Immunology*, vol. 124, no. 5, pp. 1022–1030, 2009.
- [27] S. M. Sa, P. A. Valdez, J. Wu et al., "The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis," *Journal of Immunology*, vol. 178, no. 4, pp. 2229–2240, 2007.
- [28] E. Toichi, G. Torres, T. S. McCormick et al., "An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis," *Journal of Immunology*, vol. 177, no. 7, pp. 4917–4926, 2006.
- [29] M. Jinushi and H. Tahara, "Cytokine gene-mediated immunotherapy: current status and future perspectives," *Cancer Science*, vol. 100, no. 8, pp. 1389–1396, 2009.
- [30] M. N. Alonso, M. T. Wong, A. L. Zhang et al., "T(H)1, T(H)2, and T(H)17 cells instruct monocytes to differentiate into specialized dendritic cell subsets," *Blood*, vol. 118, pp. 3311–3320, 2011.
- [31] M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al., "Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells," *Journal of Investigative Dermatology*, vol. 128, no. 5, pp. 1207–1211, 2008.
- [32] Z. Yao, S. L. Painter, W. C. Fanslow et al., "Human IL-17: a novel cytokine derived from T cells," *Journal of Immunology*, vol. 155, no. 12, pp. 5483–5486, 1995.
- [33] K. E. Nograles, L. C. Zaba, E. Guttman-Yassky et al., "Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways," *British Journal of Dermatology*, vol. 159, no. 5, pp. 1092–1102, 2008.
- [34] K. E. Nograles, B. Davidovici, and J. G. Krueger, "New Insights in the Immunologic Basis of Psoriasis," *Seminars in Cutaneous Medicine and Surgery*, vol. 29, no. 1, pp. 3–9, 2010.
- [35] T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto, "Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells," *Nature Immunology*, vol. 10, no. 8, pp. 857–863, 2009.
- [36] S. Trifari, C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits, "Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells," *Nature Immunology*, vol. 10, no. 8, pp. 864–871, 2009.
- [37] N. Yawalkar, S. Karlen, R. Hunger, C. U. Brand, and L. R. Braathen, "Expression of interleukin-12 is increased in psoriatic skin," *Journal of Investigative Dermatology*, vol. 111, no. 6, pp. 1053–1057, 1998.
- [38] E. Lee, W. L. Trepicchio, J. L. Oestreicher et al., "Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris," *Journal of Experimental Medicine*, vol. 199, no. 1, pp. 125–130, 2004.
- [39] S. Aggarwal, N. Ghilardi, M. H. Xie, F. J. De Sauvage, and A. L. Gurney, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17," *Journal of Biological Chemistry*, vol. 278, no. 3, pp. 1910–1914, 2003.
- [40] G. Piskin, R. M. R. Sylva-Steenland, J. D. Bos, and M. B. M. Teunissen, "In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin," *Journal of Immunology*, vol. 176, no. 3, pp. 1908–1915, 2006.
- [41] N. Yawalkar, G. G. Tschanner, R. E. Hunger, and A. S. Hassan, "Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis," *Journal of Dermatological Science*, vol. 54, no. 2, pp. 99–105, 2009.
- [42] J. Luo, S. J. Wu, E. R. Lacy et al., "Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab," *Journal of Molecular Biology*, vol. 402, no. 5, pp. 797–812, 2010.
- [43] J. D. Croxtall, "Ustekinumab. A review of its use in the management of moderate to severe plaque psoriasis," *Drugs*, vol. 71, pp. 1733–1753, 2011.
- [44] C. L. Kauffman, N. Aria, E. Toichi et al., "A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis," *Journal of Investigative Dermatology*, vol. 123, no. 6, pp. 1037–1044, 2004.
- [45] C. L. Leonardi, A. B. Kimball, K. A. Papp et al., "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76 week results from a randomized, double-blind, placebo-controlled trial (Phoenix 1)," *The Lancet*, vol. 371, pp. 1665–1674, 2008.
- [46] E. Rallis, S. Kintzoglou, and C. Verros, "Ustekinumab for rapid treatment of nail psoriasis," *Archives of Dermatology*, vol. 146, no. 11, pp. 1315–1316, 2010.
- [47] P. R. Mangan, L. E. Harrington, D. B. O'Quinn et al., "Transforming growth factor- β induces development of the T H17 lineage," *Nature*, vol. 441, no. 7090, pp. 231–234, 2006.
- [48] E. Bettelli, Y. Carrier, W. Gao et al., "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells," *Nature*, vol. 441, no. 7090, pp. 235–238, 2006.
- [49] B. S. McKenzie, R. A. Kastelein, and D. J. Cua, "Understanding the IL-23-IL-17 immune pathway," *Trends in Immunology*, vol. 27, no. 1, pp. 17–23, 2006.
- [50] M. A. Lowes, A. M. Bowcock, and J. G. Krueger, "Pathogenesis and therapy of psoriasis," *Nature*, vol. 445, no. 7130, pp. 866–873, 2007.
- [51] Z. Chen and J. J. O'Shea, "Th17 cells: a new fate for differentiating helper T cells," *Immunologic Research*, vol. 41, no. 2, pp. 87–102, 2008.
- [52] K. Kikly, L. Liu, S. Na, and J. D. Sedgwick, "The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation," *Current Opinion in Immunology*, vol. 18, no. 6, pp. 670–675, 2006.
- [53] A. Asarch, O. Barak, D. S. Loo, and A. B. Gottlieb, "Th17 cells: a new therapeutic target in inflammatory dermatoses," *Journal of Dermatological Treatment*, vol. 19, no. 6, pp. 318–326, 2008.
- [54] A. Asarch, O. Barak, D. S. Loo, and A. B. Gottlieb, "Th17 cells: a new paradigm for cutaneous inflammation," *Journal of Dermatological Treatment*, vol. 19, no. 5, pp. 259–266, 2008.
- [55] K. Komura, M. Fujimoto, M. Hasegawa et al., "Increased serum interleukin 23 in patients with systemic sclerosis," *Journal of Rheumatology*, vol. 35, no. 1, pp. 120–125, 2008.
- [56] J. M. Larsen, C. M. Bonefeld, S. S. Poulsen, C. Geisler, and L. Skov, "IL-23 and TH17-mediated inflammation in human allergic contact dermatitis," *Journal of Allergy and Clinical Immunology*, vol. 123, no. 2, pp. 486–492, 2009.
- [57] Y. Zhao, A. Balato, R. Fischelevich, A. Chapoval, D. L. Mann, and A. A. Gaspari, "Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis," *British Journal of Dermatology*, vol. 161, no. 6, pp. 1301–1306, 2009.

- [58] C. Ryan, B. Thrash, R. B. Warren, and A. Menter, "The use of ustekinumab in autoimmune disease," *Expert Opinion on Biological Therapy*, vol. 10, no. 4, pp. 587–604, 2010.
- [59] C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. M. Li, P. T. Y. Wong, and C. W. K. Lam, "Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity," *Clinical Immunology*, vol. 127, no. 3, pp. 385–393, 2008.
- [60] K. Shah, W. W. Lee, S. H. Lee et al., "Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus," *Arthritis Research and Therapy*, vol. 12, no. 2, article R53, 2010.
- [61] H. R. Kim, H. S. Kim, M. K. Park, M. L. Cho, S. H. Lee, and H. Y. Kim, "The clinical role of IL-23p19 in patients with rheumatoid arthritis," *Scandinavian Journal of Rheumatology*, vol. 36, no. 4, pp. 259–264, 2007.
- [62] C. Schmidt, T. Giese, B. Ludwig et al., "Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis," *Inflammatory Bowel Diseases*, vol. 11, no. 1, pp. 16–23, 2005.
- [63] W. Lew, J. Y. Chang, J. Y. Jung, and D. Bang, "Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease," *British Journal of Dermatology*, vol. 158, no. 3, pp. 505–511, 2008.